Video of Dan and Bola about making medicines.

Pushing the boundaries of science to discover, develop and deliver life-changing medicines

We make medicines that address serious medical conditions across multiple therapeutic areas. Our nine FDA-approved medicines are only the beginning of our quest to solve the human body's most complex mysteries and positively impact lives.

Regeneron-Invented FDA-Approved Medicines

About our medicines

advancing our medicines in 2021:
key regulatory updates

In 2021, our medicines reached more people than ever through expanded indications and new regulatory approvals. These regulatory milestones occurred between January 2021 and April 2022.
Investigational indications not yet approved by health authorities or regulatory agencies.

EYLEA logo


Submitted regulatory application to the European Commission (EC) for retinopathy of prematurity
DUPIXENT® (dupilumab) Injection logo.

IL-4R antibody

LIBTAYO® (cemiplimab-rwlc) logo.

PD-1 inhibitor

Evkeeza® (evinacumab-dgnb) Injection logo.

ANGPTL3 inhibitor

U.S. Food and Drug Administration (FDA)
European Commission (EC)
Approved by the FDA and EC for homozygous familial hypercholesterolemia (HoFH) Established license and collaboration agreement with Ultragenyx Pharmaceutical Inc. to clinically develop, commercialize and distribute outside of U.S.
PRALUENT® (alirocumab) Injection logo.

PCSK9 inhibitor

U.S. Food and Drug Administration (FDA) Approved by the FDA as add-on treatment for homozygous familial hypercholesterolemia (HoFH)
Back to top